Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis
- PMID: 21415580
- PMCID: PMC3304612
- DOI: 10.3350/kjhep.2010.16.4.369
Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis
Abstract
Background/aims: Liver biopsy is a standard method for diagnosis of liver cirrhosis in patients with chronic hepatitis. Because liver biopsy is an invasive method, non-invasive methods have been used for diagnosis of compensated liver cirrhosis in patients with chronic hepatitis. The current study was designed to evaluate the usefulness of ultrasonography and routine blood tests for diagnosis of compensated liver cirrhosis in patients with chronic viral hepatitis.
Methods: Two hundred three patients with chronic viral hepatitis who underwent liver biopsy were included in this study and ultrasonography and routine blood tests were analyzed retrospectively. Ultrasonographic findings, including surface nodularity, parenchyma echogenecity, and spleen size, were evaluated. The diagnostic accuracy of ultrasonography and routine blood tests were examined.
Results: Discriminant analysis with forward stepwise selection of variables showed that liver surface nodularity, platelet count, and albumin level were independently associated with compensated liver cirrhosis (p<0.05). Cross-tabulation revealed that the following 4 variables had >95% specificity: platelet count <100,000 /uL; albumin level <3.5 g/dL; INR >1.3; and surface nodularity. If at least one of the four variables exists in a patient with chronic viral hepatitis, we can predict liver cirrhosis with 90% specificity and 61% sensitivity.
Conclusions: These results suggest that four variables (platelet count <100,000 /uL, albumin level <3.5 g/dL, INR >1.3, and surface nodularity) can be used for identification of liver cirrhosis in patients with chronic viral hepatitis with high specificity.
Similar articles
-
[Ultrasonic scores combined with blood indexes for screening and predicting compensated liver cirrhosis in chronic hepatitis B patients].Nan Fang Yi Ke Da Xue Xue Bao. 2008 Dec;28(12):2157-60. Nan Fang Yi Ke Da Xue Xue Bao. 2008. PMID: 19114345 Chinese.
-
Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C.Hepatogastroenterology. 2002 Mar-Apr;49(44):478-81. Hepatogastroenterology. 2002. PMID: 11995477
-
Model consisting of ultrasonographic and simple blood indexes accurately identify compensated hepatitis B cirrhosis.J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1228-34. doi: 10.1111/j.1440-1746.2008.05421.x. Epub 2008 Jul 10. J Gastroenterol Hepatol. 2008. PMID: 18637057
-
Liver fibrosis in chronic viral hepatitis: an ultrasonographic study.World J Gastroenterol. 2003 Nov;9(11):2484-9. doi: 10.3748/wjg.v9.i11.2484. World J Gastroenterol. 2003. PMID: 14606081 Free PMC article. Clinical Trial.
-
What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy.J Hepatol. 1997 Dec;27(6):979-85. doi: 10.1016/s0168-8278(97)80140-7. J Hepatol. 1997. PMID: 9453422 Clinical Trial.
Cited by
-
Accuracy of routine clinical ultrasound for staging of liver fibrosis.J Clin Imaging Sci. 2012;2:58. doi: 10.4103/2156-7514.101000. Epub 2012 Sep 25. J Clin Imaging Sci. 2012. PMID: 23230540 Free PMC article.
-
Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases.Front Med. 2015 Mar;9(1):63-71. doi: 10.1007/s11684-014-0342-2. Epub 2014 Jul 7. Front Med. 2015. PMID: 25001101
-
Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.Oncotarget. 2017 Mar 7;8(10):16498-16506. doi: 10.18632/oncotarget.14954. Oncotarget. 2017. PMID: 28157705 Free PMC article.
-
Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study.Infect Drug Resist. 2019 Apr 1;12:745-757. doi: 10.2147/IDR.S185120. eCollection 2019. Infect Drug Resist. 2019. PMID: 31015765 Free PMC article.
-
Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.Am J Gastroenterol. 2017 Mar;112(3):460-470. doi: 10.1038/ajg.2016.480. Epub 2016 Oct 25. Am J Gastroenterol. 2017. PMID: 27779194
References
-
- Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990;8(Suppl):S18–S20. discussion S21-23. - PubMed
-
- Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(3 Suppl 1):62S–65S. - PubMed
-
- Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National institutes of health consensus development conference statement: management of hepatitis B. Hepatology. 2009;49(5 Suppl):S4–S12. - PubMed
-
- Paik SW. Goals of treatment, indication, and treatment for chronic hepatitis C. Korean J Gastroenterol. 2008;51:368–371. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical